Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data
13 Agosto 2024 - 4:50PM
AllPennyStocks.com
A California-based biotech company is finding
early success on Tuesday after the company announced positive
preliminary data of Vebreltinib in patients with non-CNS met
fusion...
To read the full story on AllPennyStocks.com, click
here.
Grafico Azioni Apollomics (NASDAQ:APLMW)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Apollomics (NASDAQ:APLMW)
Storico
Da Feb 2024 a Feb 2025